Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery establishes US Office in Cambridge, MA

Sygnature Discovery is continuing the expansion of its operations with the opening of its first US office, located in Harvard Square, Cambridge, Massachusetts.

Since its inception in 2004, Sygnature has worked closely with a range of pharmaceutical and biotech clients across the USA to conduct high quality research towards developing new and innovative medicines. To foster an even stronger commitment to the US market and to its US clients, earlier in 2018, Sygnature appointed its first US based business development representative to build on its long-standing North American presence. The USA is Sygnature Discovery’s largest market and with the new office location the company is further strengthening its commitment to better serving its US customer base.

Commenting on the expansion, CEO Dr Simon Hirst said: “Clients from all over the world come to Sygnature because we are able to offer not only a high-quality, fully-integrated drug discovery and pre-clinical service, but we also have the flexibility to provide stand-alone medicinal chemistry, in vitro biology, computational chemistry, DMPK and pre-clinical experimental services through our subsidiary company, RenaSci. As a business we have seen significant growth outside of the UK in recent years; particularly in the USA. The Boston and Cambridge area is a key life sciences hub and our office location there will ensure that we are closer to many of our key customers, both current and potential.”

The Harvard Square office is the second location Sygnature adds this year, following the news in August 2018 announcing our new DMPK facility in Alderley Park in Cheshire, UK.

We look forward to welcome you to our new office, get in touch to book a meeting or let us know if you just want to pop in for a coffee!

Latest News

View All

Sygnature Discovery establishes US Office in Cambridge,…

Towards the Holy Grail of Computational Chemistry

Sygnature Discovery announces multi-target drug discovery deal…

Dr. Scott Pollack – IDO Inhibitors and…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.